Publication: Impediment of the Progressions of Microalbuminuria and Hyperlipidemia in Normotensive Type 2 Diabetes by Low-Dose Ramipril
3
Issued Date
1998-09-01
Resource Type
ISSN
01252208
Other identifier(s)
2-s2.0-2442563861
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.81, No.9 (1998), 670-680
Suggested Citation
Somboon Vongterapak, Soontaree Nakasatien, Monta Suppanich, Chanika Surasingchaidet, Mayura Tepkasetkul, Boonsong Ongphiphadhanakul, Thep Himathongkam, Winai Dahlan, Tawee Anuntakulnatee, Worawit Kittipoom, Chattip Tamwiwat, Pongamorn Bunnag, Rajata Rajatanavin Impediment of the Progressions of Microalbuminuria and Hyperlipidemia in Normotensive Type 2 Diabetes by Low-Dose Ramipril. Journal of the Medical Association of Thailand. Vol.81, No.9 (1998), 670-680. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/18493
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Impediment of the Progressions of Microalbuminuria and Hyperlipidemia in Normotensive Type 2 Diabetes by Low-Dose Ramipril
Other Contributor(s)
Abstract
In a randomized, double-blind, placebo-controlled study, we investigated in normotensive type 2 diabetics with microalburninuria the effect of ramipril, an ACE inhibitor, on urine albumin excretion and serum lipids. A total of 1,882 patients were screened for urine microalbumin consecutively by dipstick test, Rapi Tex®-Albumin test and RIA. The final 28 normotensive and microalbuminuric patients were assigned to receive either ramipril (1.25 mg/d, n=16) or placebo (n=12) for 12 weeks. Throughout the study, both groups had no changes in blood pressure, fasting plasma glucose, HbA1C, serum creatinine and electrolytes and no difference in creatinine clearance. At week 12 only the placebo group showed the significant increment of urine albumin excretion and triacylglycerol (30.6±38.3 to 39.0±19.7 and 167±64 to 208±77 mg/dl, respectively) but the decrement of HDL-cholesterol (46±16 to 35±6 mg/dl). During a 3 month period, increased urine albumin excretion was observed in normotensive type 2 diabetes with microalbuminuria who received only placebo. We conclude that ramipril may arrest the progression of albumin excretion and had favorable effects on serum lipids. Ramipril was safe and well-tolerated without untoward side effects during the study period.